We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

406 hedge funds and large institutions have $17.3B invested in Alexion Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 406 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more call options, than puts

Call options by funds: $149M | Put options by funds: $97.1M

Holders
406
Holders Change
+406
Holders Change %
–
% of All Funds
13.25%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.2%
New
406
Increased
–
Reduced
–
Closed
–
Calls
$149M
Puts
$97.1M
Net Calls
+$51.9M
Net Calls Change
+$51.9M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
AAM
226
Aberdeen Asset Management
United Kingdom
$1.99M +$2.08M +21,600 New
EVM
227
Eaton Vance Management
Massachusetts
$1.97M +$2.06M +21,393 New
NG
228
NatWest Group
United Kingdom
$1.97M +$2.06M +21,342 New
PAM
229
Panagora Asset Management
Massachusetts
$1.96M +$2.05M +21,259 New
GI
230
GLG Inc
New York
$1.95M +$2.03M +21,087 New
GIA
231
Gateway Investment Advisers
Ohio
$1.93M +$2.01M +20,905 New
MOACM
232
Mutual of America Capital Management
New York
$1.88M +$1.97M +20,423 New
PA
233
Para Advisors
New York
$1.84M +$1.93M +20,000 New
MSU
234
Mizuho Securities USA
New York
$1.82M +$1.9M +19,752 New
PCM
235
Palisade Capital Management
New Jersey
$1.8M +$1.88M +19,560 New
RIA
236
Rushmore Investment Advisors
Texas
$1.78M +$1.86M +19,324 New
VCAM
237
Valentine Capital Asset Management
California
$1.76M +$1.84M +19,082 New
ACH
238
ArrowMark Colorado Holdings
Colorado
$1.71M +$1.78M +18,500 New
Jacobs Levy Equity Management
239
Jacobs Levy Equity Management
New Jersey
$1.69M +$1.76M +18,310 New
ClearBridge Investments
240
ClearBridge Investments
New York
$1.69M +$1.76M +18,290 New
OPERF
241
Oregon Public Employees Retirement Fund
Oregon
$1.69M +$1.76M +18,287 New
FC
242
Fiera Capital
New York
$1.66M +$1.73M +18,000 New
KCG
243
Knight Capital Group
$1.66M +$1.73M +17,989 New
NLI
244
Nippon Life Insurance
Japan
$1.65M +$1.72M +17,890 New
FCBT
245
First Citizens Bank & Trust
North Carolina
$1.64M +$1.71M +17,786 New
WCM
246
Washington Capital Management
Washington
$1.61M +$1.68M +17,468 New
HHC
247
Hutchin Hill Capital
New York
$1.6M +$1.67M +17,300 New
M&T Bank
248
M&T Bank
New York
$1.58M +$1.65M +17,130 New
SAM
249
Securian Asset Management
Minnesota
$1.57M +$1.64M +17,054 New
Calamos Advisors
250
Calamos Advisors
Illinois
$1.57M +$1.64M +17,000 New
8 9
10
11 12

ALXN Hedge Fund Activity: Q2 2013 in Review

406 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2013, worth a combined $17.3B.

Buyers outnumbered sellers: 406 funds opened new ALXN positions and 0 closed out — a net gain of 406 holders — while 0 added to existing stakes and 0 trimmed.

  • 406 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $17.3B of Alexion Pharmaceuticals stock for Q2 2013.
  • 406 funds opened new Alexion Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +406 holders.

Based on aggregated 13F filings for Q2 2013.